Skip to content

Ketamine for depression: all studies

Page 75 of 178: studies 741 to 750 of 1,775, newest first. Back to the ketamine for depression overview

Research

Navigating Treatment-Resistant Major Depressive Disorder With Suicidal Ideation: Exploring the Efficacy of Spravato (Esketamine) in an 86-Year-Old Male.

Cureus December 1, 2024 Aarman P Jivraj, Katherine A Heimer, Christopher J Wukovits et al. 1 citation

This case study examines the novel application of Spravato (intranasal esketamine) to address treatment-resistant Major Depressive Disorder (MDD) in an 86-year-old patient. Notably, this represents one of the oldest documented individuals to be administered intranasal esketamine for a diagnosis of Treatment-Resistant Depression (TRD) alongside suicidal ideation. This case study contributes to...

The role of ketamine and its enantiomer in managing depression and pain in cancer patients: A narrative review.

Journal of Anesthesia and Translational Medicine December 1, 2024 Michael S Bodnar, Sierra Barber, Heather S L Jim et al. 3 citations

Depression and pain are common comorbidities in cancer patients, and ketamine, a dissociative anesthetic, has shown potential in managing both. This review summarizes current literature on ketamine and its enantiomer, esketamine, in managing depression and pain in the oncologic population. Studies indicate that sub-anesthetic doses of intravenous ketamine and esketamine can alleviate...

DOI: 10.1016/j.jatmed.2024.10.005 (opens in new tab) Full text (opens in new tab) Anesthesia Pain management Ketamine therapy Cancer treatment +2

Treatment-resistant depression: Established and emerging therapies.

The Nurse Practitioner December 1, 2024 Leesa A McBroom, Melissa Timmons 3 citations

In 2023, the percentage of people in the US who experienced depression in their lifetime was at an all-time high of 29%. Depression causes considerable distress and functional impairment affecting quality of life, employment, and interpersonal relationships. Many patients fail to respond to treatment with antidepressants and psychological-behavioral therapy, resulting in a condition known as...

DOI: 10.1097/01.NPR.0000000000000258 (opens in new tab) Full text (opens in new tab) Esketamine Electroconvulsive therapy Transcranial magnetic stimulation Treatment-resistant depression trd +5

Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta‐analyses of randomized controlled trials

Psychiatry and Clinical Neurosciences Reports December 1, 2024 Itsuki Terao, Wakako Kodama

Abstract The individual efficacy and safety of intravenous racemic (IV) ketamine, psilocybin, and theta burst stimulation (TBS) for major depressive disorder have been demonstrated through meta‐analyses of randomized controlled trials (RCTs), but the comparative usefulness of these novel treatments has not yet been fully examined. We systematically searched the CENTRAL, Medline, CINHAL, and...

Personalized use of ketamine and esketamine for treatment-resistant depression.

Translational Psychiatry November 29, 2024 Gustavo C Medeiros, Isabella Demo, Fernando S Goes et al. 32 citations

A large and disproportionate portion of the burden associated with major depressive disorder (MDD) is due to treatment-resistant depression (TRD). Intravenous (R,S)-ketamine (ketamine) and intranasal (S)-ketamine (esketamine) are rapid-acting antidepressants that can effectively treat TRD. However, there is variability in response to ketamine/esketamine, and a personalized approach to their use...

DOI: 10.1038/s41398-024-03180-8 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Depression treatment Ketamine therapy Mental health breakthroughs +1

Maintenance Intramuscular Ketamine-Assisted Psychotherapy, a Retrospective Chart Review of Efficacy, Adverse Events, and Dropouts from a Community Practice.

Journal of Psychoactive Drugs November 22, 2024 Wesley C Ryan, Boris D. Heifets 2 citations

The use of ketamine and ketamine-assisted psychotherapy (KAP) for treatment of depression has grown dramatically, though much of these data are short term. The clinical profile of maintenance treatment remains poorly characterized. We assessed maintenance KAP for efficacy, tolerability, and reasons for dropout. This observational study retrospectively analyzed electronic health records from an...

The effect and mechanism of low-dose esketamine in neuropathic pain-related depression-like behavior in rats.

Brain Research November 15, 2024 Lijuan Wang, Shuwu Zhao, Jiali Shao et al. 7 citations

Clinical evidence suggests that Esketamine (ESK) is an effective treatment for depression. However, the effects of Esketamine in treating depression-like behavior induced by neuropathic pain is unclear. The underlying molecular mechanisms require further investigation to provide new therapeutic targets for the treatment of clinical neuropathic pain-related depression. A neuropathic pain-related...

DOI: 10.1016/j.brainres.2024.149117 (opens in new tab) Full text (opens in new tab) Homer1a Mglur5 Depression therapy Neuropathic pain treatment +2

Effects of Different Anesthesia Applications on Mood, Depression, and Anxiety Levels in Burn Patients.

Journal of Burn Care & Research November 14, 2024 Ayça Tuba Dumanlı Özcan, Betül Akaycan, Serdar Süleyman Can et al. 4 citations

Adequate and effective pain management and prevention of depression are essential in patients with burns. This study aims to explore the effects of ketamine sedation in patients with burns in terms of mood disorders, depression, anxiety, and suicidality during postoperative follow-up in the intensive care unit. This study targeted subjects aged 18-65 years, in the ASA I-II class, with basic...

DOI: 10.1093/jbcr/irae105 (opens in new tab) Full text (opens in new tab) Depression Patients with burns Suicidal tendencies Mental health +4

Ketamine attenuates kidney damage and depression-like behaviors in mice with cisplatin-induced acute kidney injury.

Translational Psychiatry November 9, 2024 Tianwen Huang, Yangyang He, Ruijuan Cheng et al. 5 citations

Acute kidney injury (AKI) is a serious condition characterized by decreased urine output, often accompanied by psychiatric symptoms like depression. However, there are limited pharmacological treatments available for AKI and its associated depressive symptoms. In this study, we investigated whether cisplatin-induced AKI in mice leads to depression-like behaviors and whether ketamine could...

DOI: 10.1038/s41398-024-03176-4 (opens in new tab) Full text (opens in new tab) Ketamine therapy Mental health treatment Nephrology research Psychopharmacology +1

S-ketamine alleviates depression-like behavior and hippocampal neuroplasticity in the offspring of mice that experience prenatal stress.

Scientific Reports November 6, 2024 Yan Zhang, Chu-Ke Wei, Ping Wang et al. 12 citations

Prenatal stress exerts long-term impact on neurodevelopment in the offspring, with consequences such as increasing the offspring's risk of depression in adolescence and early adulthood. S-ketamine can produce rapid and robust antidepressant effects, but it is not clear yet whether and how S-ketamine alleviates depression in prenatally stressed offspring. The current study incestigated the...